Clinical Trial Update: Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel and cisplatin (DDP) combined with anlotinib as first-line therapy for advanced esophageal squamous cell carcinoma; current s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• DDP
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN